Dr. Carina Kern is a British geneticist and the CEO of LinkGevity, a biotech company developing therapeutics for aging-related diseases. She holds a PhD from University College London and has researched aging biology extensively. At LinkGevity, she leads AI-driven biomedical data analysis and the Blueprint Theory of aging, identifying triggers of deterioration. Her work includes Anti-Necrotic™ therapeutics for cellular resilience, with applications in space and organ preservation. She is also the Scientific Chair of the CleanTech Challenge and President of the London Evolutionary Research Network.